Reboot

Reboot Sciences is developing Reboot 001, a therapy that prevents secondary infections in trauma and ICU patients and saves lives. As a startup, we focus on early development and seek collaboration later on to bring the product to market.

This treatment reverses immunoparalysis - a condition where the immune system shuts down after severe injury - without the limitations of current approaches that suppress T-cell function.

What makes Reboot 001 special is that it gives the immune system a boost at precisely the moment when the body is struggling the most.

For trauma and ICU patients — civilian and military

Immunoparalysis is common after burns, crush injuries, and major surgery.

In military situations, the risk is even greater: more survivors of explosions and complex injuries, followed by long stays in intensive care—precisely the conditions in which immunoparalysis strikes.

In animal studies, Reboot 001 showed promising results. The drug helped mice survive a severe infection.

With 30% of ICU deaths attributed to hospital-acquired infections in immune-compromised patients, we address a €2B+ market with no approved therapies.

We are seeking seed funding to complete preclinical validation and secure European Defence Fund co-financing for military trauma applications.

More info: rebootsciences.com